South Africa on Sunday said it would suspend its rollout of the Oxford-AstraZeneca vaccine after initial trials showed disappointing results against the B.1.351 variant of COVID-19. The country has received 1 million doses of the jab. It had planned to start using it to vaccinate frontline healthcare workers from mid-February. The study, involving around 2,000 people, found the vaccine offered minimal protection against mild and moderate cases of COVID-19 but it has not yet been peer-reviewed. Scientists will be studying whether or not the AstraZeneca vaccine is effective in preventing severe disease and death against the new variant.
The decision to reduce service fee for patents, utility models and industrial designs for students, research centres and…110 Views | the publication reaches you by | Oman News
In a significant endorsement that will support exports to European Union (EU) markets, Oman’s largest cement manufacturer, Raysut…540 Views | the publication reaches you by | Oman News
Do you have information you want to reach our readers?